Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more
Icure Pharmaceutical Incorporation (175250) - Net Assets
Latest net assets as of June 2025: ₩48.39 Billion KRW
Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has net assets worth ₩48.39 Billion KRW as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩128.95 Billion) and total liabilities (₩80.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩48.39 Billion |
| % of Total Assets | 37.53% |
| Annual Growth Rate | 29.3% |
| 5-Year Change | -46.27% |
| 10-Year Change | N/A |
| Growth Volatility | 129.21 |
Icure Pharmaceutical Incorporation - Net Assets Trend (2015–2024)
This chart illustrates how Icure Pharmaceutical Incorporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Icure Pharmaceutical Incorporation (2015–2024)
The table below shows the annual net assets of Icure Pharmaceutical Incorporation from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩60.26 Billion | +1.12% |
| 2023-12-31 | ₩59.59 Billion | -33.54% |
| 2022-12-31 | ₩89.67 Billion | -6.35% |
| 2021-12-31 | ₩95.76 Billion | -14.62% |
| 2020-12-31 | ₩112.15 Billion | +14.99% |
| 2019-12-31 | ₩97.53 Billion | +15.16% |
| 2018-12-31 | ₩84.69 Billion | +384.66% |
| 2017-12-31 | ₩17.47 Billion | +3.15% |
| 2016-12-31 | ₩16.94 Billion | +184.12% |
| 2015-12-31 | ₩5.96 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Icure Pharmaceutical Incorporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8196693059000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩18.78 Billion | 31.16% |
| Other Components | ₩131.12 Billion | 217.58% |
| Total Equity | ₩60.26 Billion | 100.00% |
Icure Pharmaceutical Incorporation Competitors by Market Cap
The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tung Ho Textile Co Ltd
TW:1414
|
$46.96 Million |
|
Wattanapat Hospital Trang Public Company Limited
BK:WPH
|
$46.96 Million |
|
Motisons Jewellers Ltd
NSE:MOTISONS
|
$46.96 Million |
|
Ray Sigorta AS
IS:RAYSG
|
$46.99 Million |
|
Tin Nghia Industrial Park Development JSC
VN:TIP
|
$46.95 Million |
|
Geodrill Limited
OTCQX:GEODF
|
$46.94 Million |
|
Hi-Lai Foods Co Ltd
TWO:1268
|
$46.94 Million |
|
Duksung Co Ltd
KO:004835
|
$46.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Icure Pharmaceutical Incorporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 58,237,722,830 to 60,260,335,000, a change of 2,022,612,170 (3.5%).
- Net income of 1,049,233,140 contributed positively to equity growth.
- Share repurchases of 170,680,000 reduced equity.
- Other factors increased equity by 1,144,059,030.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.05 Billion | +1.74% |
| Share Repurchases | ₩170.68 Million | -0.28% |
| Other Changes | ₩1.14 Billion | +1.9% |
| Total Change | ₩- | 3.47% |
Book Value vs Market Value Analysis
This analysis compares Icure Pharmaceutical Incorporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.51x to 1.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1438.20 | ₩2170.00 | x |
| 2017-12-31 | ₩1483.48 | ₩2170.00 | x |
| 2018-12-31 | ₩5762.78 | ₩2170.00 | x |
| 2019-12-31 | ₩6435.44 | ₩2170.00 | x |
| 2020-12-31 | ₩6299.89 | ₩2170.00 | x |
| 2021-12-31 | ₩3661.16 | ₩2170.00 | x |
| 2022-12-31 | ₩2399.56 | ₩2170.00 | x |
| 2023-12-31 | ₩1558.42 | ₩2170.00 | x |
| 2024-12-31 | ₩1612.55 | ₩2170.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Icure Pharmaceutical Incorporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.52%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 2.21x
- Recent ROE (1.74%) is above the historical average (-23.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -48.26% | -15.41% | 0.71x | 4.39x | ₩-3.47 Billion |
| 2016 | -19.14% | -11.89% | 0.87x | 1.86x | ₩-4.94 Billion |
| 2017 | 3.08% | 1.35% | 0.74x | 3.08x | ₩-1.21 Billion |
| 2018 | -9.31% | -23.66% | 0.28x | 1.43x | ₩-16.35 Billion |
| 2019 | -8.97% | -14.36% | 0.28x | 2.21x | ₩-18.50 Billion |
| 2020 | -11.25% | -13.99% | 0.46x | 1.74x | ₩-23.83 Billion |
| 2021 | -39.86% | -59.37% | 0.30x | 2.25x | ₩-47.74 Billion |
| 2022 | -46.58% | -70.35% | 0.26x | 2.50x | ₩-50.73 Billion |
| 2023 | -53.95% | -55.31% | 0.34x | 2.85x | ₩-37.24 Billion |
| 2024 | 1.74% | 1.52% | 0.52x | 2.21x | ₩-4.98 Billion |
Industry Comparison
This section compares Icure Pharmaceutical Incorporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Icure Pharmaceutical Incorporation (175250) | ₩48.39 Billion | -48.26% | 1.66x | $46.95 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |